News : pharmeceutical company

Uppsala, Sweden, November 16, 2010 - Orexo AB (STO: ORX) announces that its sales partner in the EU and USA for Abstral™, ProStrakan Group plc (“ProStrakan”) yesterday issued its interim report, which gave further information on progress with Abstral™, Orexo’s leading sublingual fentanyl product for treatment of breakthrough cancer pain. Abstral™ recorded sales of £14.1m (156 MSEK) in the first 10 months of the...

Key events during the period

· Net revenues amounted to MSEK 65.5 (144.6). 1)
· Cash flow from operating activities was MSEK 11.2 (-74.4).
· Abstral royalty increased to MSEK 19.5 (3.0).
· The loss after tax was MSEK 62.9 (loss: 30.5). The loss per share was SEK 2.69 (loss: 1.38).
· Cash and cash equivalents at the end of the period totaled MSEK 190.9 compared with MSEK 87.4 at the beginning of the...

Uppsala, Sweden, June 2, 2010 –Orexo AB (STO: ORX) today confirms that its partner, ProStrakan Group plc (LSE: PSK) has today announced that the US Food and Drug Administration (“FDA”) has extended the review period under the Prescription Drug User Fee Act (“PDUFA”) for AbstralTM by three months.

The FDA has issued the extension following its earlier request for additional information on the Abstral Risk...

Uppsala, February 4, 2010 – Orexo AB (STO: ORX) today confirms that its partner, ProStrakan Group plc (LSE: PSK) has announced that the New Drug Submission made by their Canadian partner, Paladin Labs Inc., for AbstralTM has been accepted for review by Health Canada, the Canadian Government Department with responsibility for public health.

AbstralTM, developed by Orexo AB is a new, rapidly disintegrating,...

Uppsala, February 2, 2010 – Orexo AB (STO: ORX) announces today that its partner Kyowa Hakko Kirin Co., Ltd. has entered a joint distribution agreement for the cancer pain drug KW-2246 (Orexo’s sublingual fentanyl product) with the pharmaceutical company Hisamitsu Pharmaceutical Co., Inc.

Kyowa Hakko Kirin is responsible for the approval process for the product in Japan and under the terms of the agreement, KW-2246...

Uppsala, November 10, 2009

Orexo AB (publ) – Interim report January-September 2009


Key events during the period
• Net revenues amounted to MSEK 208.2 (141.2).
• The loss after tax was MSEK 40.1 (loss: 88,6).
• The loss per share was SEK 1.78 (loss: 4.10).
• Cash and cash equivalents at the end of the quarter totaled MSEK 107.1 (195.7).
• In March, the US Food and Drug Administration (FDA) approved Orexo’s Edluar...

Uppsala, Sweden, 28 August, 2009 - Orexo (STO: ORX) announces it has signed an exclusive worldwide licensing agreement with a Novartis affiliate to develop and commercialise a novel product related to Orexo’s OX17 program.

Under the terms of the agreement, Novartis will fund all future development of the new product and will receive an exclusive license to all related intellectual property. Orexo will receive...